SecBot SecBot
S-3 ·Filed Aug 13, 2026

CV

CapsoVision, Inc
BEARISH
Impact 6/10
Horizonweeks Processed2mo ago SEC0001628280-26-056802
Shelf registration — potential dilution
Actionable Insight ▼ Bearish

Monitor the company's ATM sales disclosures in future 10-Qs and 8-Ks to gauge the pace of dilution. The going-concern qualification and thin book value suggest the company will likely tap the ATM aggressively. Watch for any 510(k) clearance updates on the AI-assisted CapsoCam Plus or CapsoCam Colon as potential catalysts that could slow the pace of share sales.

DirectionBearish
Confidencehigh
Horizonweeks
Latest settled — T+20d
CV ▲ +0.77% at T+20d
SHORT call ✗ call lost -0.77% · α vs SPY -2.77% · entry $6.46 → $6.51
Next anchor: T+60d in 10d
Latest observation: T+49 -17.49% FF3 residual α
Entry = T+0 close
Aug 13, 2026
via day close
T+1d
-0.23%
call +0.23% · α -0.24%
$6.45
settled 2mo ago
T+5d
-6.81%
call +6.81% · α +5.44%
$6.02
settled 2mo ago
T+20d
+0.77%
call -0.77% · α -2.77%
$6.51
settled 7w ago
T+60d
Pending
in 10d

Price Chart

Loading chart...

Executive Summary

CapsoVision filed a $250M universal shelf registration (S-3) on August 13, 2026, including a $100M ATM facility with Cantor Fitzgerald. The company had a net tangible book value of just $13.2M as of June 30, 2026, and its auditor included a going-concern explanatory paragraph in its most recent annual report. This filing signals significant potential dilution — up to ~29% of current shares outstanding at the reference price — and underscores the company's urgent need for capital to fund R&D, sales, and working capital.

Key Financial Metrics

Offering Size
$100.0M

Key Facts

  • CapsoVision filed a $250M universal shelf registration (S-3) on August 13, 2026, including a $100M at-the-market (ATM) facility with Cantor Fitzgerald.
  • The company's net tangible book value was only $13.2M ($0.26/share) as of June 30, 2026, against a $343M market cap.
  • The auditor's report on the FY2025 financial statements includes a going-concern explanatory paragraph.
  • At the $6.86 reference price, the full $100M ATM would represent ~14.6M new shares, or ~29% dilution relative to the 50.0M shares outstanding.
  • Proceeds are for general corporate purposes including sales/marketing, R&D, and working capital.
  • The company has filed 7 offering/registration documents in the last 24 months, indicating a pattern of capital raising.
  • Lock-up agreements on ~41.1M pre-IPO shares expired in early January 2026, adding potential overhang.

Financial Impact

Potential dilution of up to ~29% of shares outstanding from the $100M ATM alone, with an additional $150M available under the universal shelf. The company's net tangible book value of $13.2M would increase to $109.9M if the full ATM is sold at $6.86/share, but existing holders would see per-share book value diluted from $0.26 to $1.70.

dilutionbook valueshare count

Risk Factors

  • Significant dilution from the ATM and potential future shelf takedowns.
  • Going-concern risk highlighted by the auditor's report — the company may need to raise capital on unfavorable terms.
  • Expired lock-up on ~41.1M pre-IPO shares creates additional overhang.
  • Regulatory delays or failures for CapsoCam Colon and AI-assisted CapsoCam Plus could increase capital needs.

Market Snapshot

Exchange
Nasdaq
Sector
Electromedical & Electrotherapeutic Apparatus
Analyst Consensus
89% bullish (9 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 8 SEC documents filed with EDGAR.

DocumentAccession Number
S-3 Filing (Primary)0001628280-26-056802
Exhibit: exhibit51-sx3.htm0001628280-26-056802
Exhibit: exhibit52-sx3.htm0001628280-26-056802
Exhibit: exhibit231-sx3.htm0001628280-26-056802
Document: cvexfilingfees.htm0001628280-26-056802
Document: 0001628280-26-056802-index-headers.html0001628280-26-056802
Document: 0001628280-26-056802-index.html0001628280-26-056802
Document: 0001628280-26-056802.txt0001628280-26-056802
16 reports for CV
Performance horizon
67% Hit rate @ T+60 2 of 3 directional calls Went positive at some point 3 of 7 best @ T+20▲ +10.53%Jul 7, 2026
Filters
Rows
Reports for CV — sortable, filterable
TypeNow
Sep 28, 2026
28d ago
8-K
BULLISH ★ 6/10
$6.92awaiting T+60—$6.89 (−0.43%)
Sep 28, 2026
28d ago
Press Release
BULLISH ★ 5/10
$6.92awaiting T+60—$6.89 (−0.43%)
Sep 23, 2026
4w ago
Insider Cluster
NEUTRAL ★ 4/10
$6.17awaiting T+60—$6.89 (+11.67%)
Sep 22, 2026
4w ago
Institutional Cluster
NEUTRAL ★ 3/10
$6.30awaiting T+60—$6.89 (+9.37%)
Sep 18, 2026
5w ago
424B5
BEARISH ★ 6/10
$6.70awaiting T+60—$6.89 (−2.84%)
Aug 24, 2026
9w ago
EFFECT
BEARISH ★ 7/10
$5.83awaiting T+60—$6.89 (−18.18%)
Aug 13, 2026
10w ago
S-3
BEARISH ★ 6/10
$6.46awaiting T+60—$6.89 (−6.66%)
Jul 21, 2026
13w ago
Insider Buy
BULLISH ★ 5/10
$6.91 $6.45▼ −6.66%▼ −9.92%$6.89 (−0.29%)
Jul 10, 2026
15w ago
Insider Buy
BULLISH ★ 5/10
$6.22 $6.50▲ +4.50%▲ +0.51%$6.89 (+10.77%)
Jul 7, 2026
15w ago
Insider Buy
BULLISH ★ 5/10
$6.13 $6.32▲ +3.18%▲ +0.69%$6.89 (+12.49%)
Showing 10 of 16

US Market Status

Market Closed — Opens Wed (10h 9m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 13, 2026